| EU, Canada probe Rasilez safety after study termination - PMLiVE |
|
|
PMLiVE Earlier this week Novartis said the study of Rasilez in diabetic patients with renal impairment suggested its drug may be linked to higher levels of adverse events when added to standard treatment with an ACE inhibitor or angiotensin II receptor |